Medicine price: quote on request. Every case gets a written custom quote before you commit. Your total cost is quoted per case.
Written estimate for your case
Get my quote

Is Zevaskyn available in Bahrain? How families get Zevaskyn (prademagene zamikeracel)

A plain answer for families in Bahrain, checked against FDA, manufacturer and regulator sources.

Reviewed by the Reserve Meds clinical operations team on 17 October 2026.

Is Zevaskyn available in Bahrain?

Zevaskyn (prademagene zamikeracel) is an FDA-approved autologous cell sheet-based gene therapy for wounds in recessive dystrophic epidermolysis bullosa (RDEB). Zevaskyn is not on NHRA's Registered Medicine Price List (version dated 7 September 2026, 5,560 entries) or on its Temporary Importation Medicines List (dated 19 January 2025). We checked both on 17 October 2026. Zevaskyn is given only at specialized treatment centers, so for most families in Bahrain the realistic route is treatment at a qualified center abroad, after a referral from the treating specialist. If a hospital in Bahrain wants to give it locally, the manufacturer must agree to supply that hospital and the National Health Regulatory Authority (NHRA) must approve the import. Reserve Meds helps organize the referral and logistics. We do not prescribe.

  • Registration in Bahrain: not on NHRA's registered list (7 September 2026) or temporary importation list (19 January 2025), checked 17 October 2026.
  • Legal route: Treatment at a qualified center abroad, or a hospital import request if the manufacturer agrees.
  • Who applies: your treating specialist refers the patient to a qualified center; a hospital in Bahrain applies to NHRA only if the manufacturer agrees to supply it.
  • Timeline: We give you a written timeline estimate once we see the hospital file. The regulator and the manufacturer set their own timelines.
  • Medicine price: quote on request. Every case gets a written custom quote before you commit.

What Zevaskyn is

Zevaskyn (prademagene zamikeracel) is made by Abeona Therapeutics. The US FDA approved it on 28 April 2025 for wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). It is given as skin sheets grown from the patient's own skin cells, corrected with a working collagen gene, then applied to wounds in surgery.

Abeona makes the sheets over about 25 days. They last about 84 hours after release, so they are applied at a qualified treatment center. The surgical team will explain anesthesia and wound-care risks.

We found no approval outside the United States in public sources as of 13 October 2026.

Registration status in Bahrain

Zevaskyn is not on NHRA's Registered Medicine Price List (version dated 7 September 2026, 5,560 entries) or on its Temporary Importation Medicines List (dated 19 January 2025). We checked both on 17 October 2026. The same registered list does include other specialty therapies, such as Zolgensma, Casgevy and Elevidys, so it does cover this kind of medicine.

NHRA updates its lists. Ask the hospital pharmacy to confirm the current status with NHRA's pharmaceutical products regulation section before anything is filed.

The legal route in Bahrain

Zevaskyn is made from a skin biopsy of the patient and must be applied within about 84 hours, at a qualified treatment center with epidermolysis bullosa experience. This means treatment happens at a qualified US center.

For a family in Bahrain, that leaves two realistic routes. First, treatment at a qualified center abroad, after your specialist refers you and the center accepts the patient. Second, a hospital in Bahrain asks the manufacturer, Abeona Therapeutics, whether it will supply that hospital. If the manufacturer agrees, the hospital still needs import approval from the National Health Regulatory Authority (NHRA). We cannot promise that a manufacturer will agree.

How a hospital import request works in Bahrain, if it is ever needed:

Under NHRA Circular No. (41) of 2020, government and private hospitals must get NHRA's permission before they issue a purchase order for a medicine that is not registered in Bahrain.

The circular asks that the medicine is important and has no registered alternative in Bahrain, is registered with the Gulf Health Council or in a GCC country, is registered with a reference authority such as the US FDA, and is marketed in its country of origin.

Some medicines for rare diseases, emergencies and tumors with no registered alternative can be excused from the registration and marketing conditions, through NHRA's list of emergency medicines or with Board approval.

The request goes to NHRA by email with the application form, a Certificate of Pharmaceutical Product (CPP) or registration certificate from a reference authority, and a Good Manufacturing Practice (GMP) certificate. NHRA's 2022 application form is signed by the importing hospital, the agent or the marketing authorization holder, who takes full responsibility for the product's quality and safety.

Who does what

  • Your treating specialist decides whether Zevaskyn is right for the patient and writes the letter.
  • The hospital refers the patient, or files a local import request if that becomes possible.
  • The National Health Regulatory Authority (NHRA) decides whether to approve an import of a medicine that is not registered.
  • Abeona Therapeutics makes Zevaskyn and decides where it can be supplied.
  • Reserve Meds can help organize records and logistics, and keeps your family updated. We do not give medical advice.

Documents you will usually need

  • A referral letter from the treating specialist: diagnosis, test results and why this treatment is being considered
  • Genetic or laboratory reports that confirm the diagnosis, translated into English where needed
  • Recent clinic notes, imaging and a list of past treatments
  • Passport and travel documents, if treatment happens abroad
  • A funding plan: personal funds, insurer approval, or a government treatment-abroad decision

Timeline, step by step

  1. Referral. Your specialist prepares a referral letter and the medical records.
  2. Center review. A qualified treatment center reviews the records and decides whether the patient is eligible.
  3. Funding and travel. The family confirms funding and plans travel and accommodation.
  4. Preparation. The center runs tests and, for some products, collects cells or tissue to make the treatment.
  5. Treatment and follow-up. The patient is treated and then followed up by the center and the home specialist.

We give you a written timeline estimate once we see the hospital file. The regulator and the manufacturer set their own timelines.

What Zevaskyn costs

Medicine price: quote on request. Your total cost depends on the dose, shipping, import steps and coordination. Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

How Reserve Meds helps

Reserve Meds is a digital health company. Medicines are supplied through a US-licensed pharmaceutical wholesale partner. We help your doctor and hospital prepare the file, arrange US supply and shipping once approval is in place, and keep your family updated. We coordinate access to FDA-approved medicines only. We do not prescribe, and we do not decide what the regulator approves.

Ask us about Zevaskyn in Bahrain

Tell us the medicine, the country, and how to reach you. We reply within one business day. On WhatsApp we usually reply the same day.

Message us on WhatsApp Already have a case? Sign in

Your coordination fee is quoted in writing for your case before you commit. No hidden charges.

Frequently asked questions

Is Zevaskyn approved in Bahrain?

Zevaskyn is not on NHRA's Registered Medicine Price List (version dated 7 September 2026, 5,560 entries) or on its Temporary Importation Medicines List (dated 19 January 2025). We checked both on 17 October 2026. The same registered list does include other specialty therapies, such as Zolgensma, Casgevy and Elevidys, so it does cover this kind of medicine. NHRA updates its lists. Ask the hospital pharmacy to confirm the current status with NHRA's pharmaceutical products regulation section before anything is filed.

Who applies for permission to use Zevaskyn in Bahrain?

For treatment abroad, your specialist refers the patient to a qualified center. For a local hospital import, the hospital applies to the National Health Regulatory Authority (NHRA), and the manufacturer must agree to supply.

How long does it take to get Zevaskyn in Bahrain?

It depends on the center's review, the patient's eligibility and how long the treatment takes to prepare. We give you a written timeline estimate once we see the hospital file. The regulator and the manufacturer set their own timelines.

How much does Zevaskyn cost?

Medicine price: quote on request. Your total cost, including shipping, import steps and coordination, is quoted in writing for your case before you commit. No hidden charges.

Can Zevaskyn be given in Bahrain instead of abroad?

Only if the manufacturer agrees to supply a hospital in Bahrain and NHRA approves the import. We will tell you honestly if that is not possible today.

Sources

Checked on 17 October 2026. Regulator rules and lists change. Your hospital pharmacy confirms the current procedure before filing.

  1. FDA: ZEVASKYN (prademagene zamikeracel) product page, approved 28 Apr 2025
  2. MedCity News: Abeona wins FDA approval for Zevaskyn
  3. NHRA Bahrain: Registered Medicine Price List, version dated 7 September 2026 (Excel, 5,560 entries)
  4. NHRA Bahrain: Temporary Importation Medicines List, dated 19 January 2025 (Excel)
  5. NHRA Bahrain: Circular No. (41) of 2020, procedures for importing non-registered medicines and pharmaceutical products
  6. NHRA Bahrain: Application Form for Import of Unregistered Medicines and Pharmaceuticals (14 July 2022)

Related

WhatsApp